Friday: September 25, 2020
10:00-11:30 (EST)
Session I: Genomics and epigenomics of MM:
Chairs: Gareth Morgan & Ola Landgren
- 1q and the pathogenesis of MM; Samir Parekh
- Mutational signatures and the evolution of MM; Francesco Maura
- Insights from functional genomics in MM; Constantine Mitsiades
- Evolving insights into the t(4;14); Gareth Morgan
- The clinical and molecular relationship of MGUS and MM; Ola Landgren
Panel Discussion: Chairs and invited speakers
11:30-12:55
Session II: Novel Targets
Chairs: Ken Anderson & Maria V Mateos
- Strategies targeting super enhancers in MM; Wee Joo
- Update on ubiquitin ligases, Celmods and new IMiDs; Ken Anderson
- Anti-BCMA and other immunoconjugates; Suzanne Trudel
- Targeting MCL1 and BCL2 inhibition; Larry Boise
- Therapeutic trials in MGUS and SMM; Maria V Mateos
- PIKfyve- a novel target in Myeloma; Keith Stewart
- Endpoints and therapy options for amyloidosis; Suzanne Lentzsch
Panel Discussion: Chairs and invited speakers
End Scientific Session, Day 1
Saturday: September 26, 2020
10:00-11:30
Session III: Evaluating new therapies
Chairs: Ivan Borrello & Irene Ghobriel
- The MM niche, quiescence and BMP6; Sarah Gooding
- Single cell analysis of myeloma and its microenvironment; Irene Ghobrial
- Pre-clinical disease models of MM; Marta Chiesi
- The current therapeutic standard for MM; Pieter Sonneveld
- Molecular and clinical definitions of high-risk MM; Leif Bergsagel
- Genetic changes associated with relapse; Jonathan Keats
Panel Discussion: Chairs and invited speakers
11:30-13:00
Session IV: T-cell engagement strategies:
Chairs: Hermann Einsele & Yi Lin
- Clinical data and trial data on bi-specific antibodies for MM; Hermann Einsele
- Clinical data and trial update of anti-BCMA CAR-Ts; Yi Lin
- Optimizing and manufacturing CAR-T constructs; Eric Smith
- Mechanisms of resistance to immune oncology drugs; Leo Rasche
Panel Discussion: Chairs and invited speakers
End Scientific Session, Day 2 – End of Meeting
